{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:47:40Z","timestamp":1794023260124,"version":"4.8.0"},"reference-count":81,"publisher":"Baishideng Publishing Group Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJGO"],"published-print":{"date-parts":[[2022,4,15]]},"DOI":"10.4251\/wjgo.v14.i4.808","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T07:21:30Z","timestamp":1649920890000},"page":"808-819","source":"Crossref","is-referenced-by-count":15,"title":["Vasoactive intestinal peptide secreting tumour: An overview"],"prefix":"10.4251","volume":"14","author":[{"given":"Esther","family":"Una Cidon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(58)90075-5"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1159\/000335591"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-007-9566-6"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.282.6278.1767"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3109\/07435800.2010.525085"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/21548331.2016.1210474"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2015-213016"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-007-0177-0"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.3615"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90425-6"},{"key":"B11","unstructured":"Belei OA, Heredea ER, Boeriu E, Marcovici TM, Cerbu S, M\u0103rginean O, Iacob ER, Iacob D, Motoc AGM, Boia ES. Verner-Morrison syndrome. Literature review. Rom J Morphol Embryol 2017; 58: 371-376"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1995.75.2.277"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.2.605"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/BF01534924"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/science.169.3951.1217"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/225863a0"},{"key":"B17","unstructured":"Dockray GJ.   Vasoactive intestinal polypeptide and related peptides. In: Walsh JH, Dockray GJ. Gut Hormones: Biochemistry and Physiology, 1st ed. New York: Raven Press, 1994: 447"},{"key":"B18","unstructured":"Meriney DK. Pathophysiology and management of VIPoma: a case study. Oncol Nurs Forum 1996; 23: 941-8; quiz 949"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1988.tb27005.x"},{"key":"B20","unstructured":"CHARLES B, COCHRANE WA. Islet cell tumour of the pancreas with chronic diarrhoea and hypokalaemia-a recently recognized syndrome. Can Med Assoc J 1960; 82: 579-586"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-8993(87)80007-0"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s0039-6109(16)44190-3"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2003.12.007"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.05.047"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1210\/en.2016-1399"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200601000-00017"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s0039-6109(05)70141-9"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2006.12.002"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1067\/msy.1998.92005"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2051"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.226"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/00003072-199406000-00014"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/00006676-200401000-00015"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1522-2586(200002)11:2<141::aid-jmri10>3.0.co;2-u"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/s0730-725x(97)00201-4"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.03967.x"},{"key":"B37","unstructured":"Schillaci O, Corleto VD, Annibale B, Scopinaro F, Delle Fave G. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours. Ital J Gastroenterol Hepatol 1999; 31 Suppl 2: S186-S189"},{"key":"B38","unstructured":"Virgolini I, Traub T, Novotny C, Leimer M, F\u00fcger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, Andreae F, Kurtaran A, Dudczak R. New trends in peptide receptor radioligands. Q J Nucl Med 2001; 45: 153-159"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.02480.x"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.142.7.946"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3121\/cmr.2017.1379a"},{"key":"B42","unstructured":"Zandee WT, Hofland J, de Herder WW.   Vasoactive Intestinal Peptide Tumor (VIPoma). 2021 Aug 28. In: Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000\u2013"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2018.10.007"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.13968"},{"key":"B45","unstructured":"Schizas D, Mastoraki A, Bagias G, Patras R, Moris D, Lazaridis II, Arkadopoulos N, Felekouras E. Clinicopathological data and treatment modalities for pancreatic vipomas: a systematic review. J BUON 2019; 24: 415-423"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2015.12.003"},{"key":"B47","unstructured":"Mekhjian HS, O'Dorisio TM. VIPoma syndrome. Semin Oncol 1987; 14: 282-291"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2014.03.002"},{"key":"B49","unstructured":"Soga J, Yakuwa Y. Vipoma\/diarrheogenic syndrome: a statistical evaluation of 241 reported cases. J Exp Clin Cancer Res 1998; 17: 389-400"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2016.3019"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.767332"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02475-2"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/BF02285194"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1023\/a:1026672022917"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1995.tb01877.x"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.142"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1159\/000051862"},{"key":"B58","doi-asserted-by":"crossref","unstructured":"O'Dorisio TM, Mekhjian HS, Gaginella TS. Medical therapy of VIPomas. Endocrinol Metab Clin North Am 1989; 18: 545-556","DOI":"10.1016\/S0889-8529(18)30381-5"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.10.010"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199202203260804"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25425"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.024"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.304"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-011-0482-2"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.4103\/1450-1147.89779"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2010.12.003"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1159\/000225951"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e31815e4557"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003825"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X13493878"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.2669"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-15-0314"},{"key":"B73","unstructured":"Chan J.   Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors. [accessed 2021 July 15]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01466036"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009290"},{"key":"B75","unstructured":"Rajdev L.   Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery. [accessed 2021 November 23]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02893930"},{"key":"B76","unstructured":"Hobday T.   Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors. [accessed 2022 January 23]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00075439"},{"key":"B77","unstructured":"Berlin J.   Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor. [accessed 2017 September 28]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02831179"},{"key":"B78","unstructured":"Chan JA.   Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors. [accessed 2022 February 3]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03375320"},{"key":"B79","unstructured":"Kulke MH.   Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery. [accessed 2021 September 9]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01229943"},{"key":"B80","unstructured":"Fan S.   Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors. [accessed 2021 August 31]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02589821"},{"key":"B81","unstructured":"Fan S.   Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors. [accessed 2021 April 15]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): U.S. National Library of Medicine. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02588170"}],"container-title":["World Journal of Gastrointestinal Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/1948-5204\/full\/v14\/i4\/808.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T07:22:05Z","timestamp":1649920925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/1948-5204\/full\/v14\/i4\/808.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":81,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.4251\/wjgo.v14.i4.808","relation":{},"ISSN":["1948-5204"],"issn-type":[{"value":"1948-5204","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,15]]}}}